Karuna Therapeutics, Inc.

China’s retaliatory tariffs mean the option of manufacturing US-originated drugs in China is making more sense than ever, at least to some local partners of US pharmaceutical companies. China imposed

It looks as though nothing will come of the takeover talks PureTech Health has held with Nordic Capital Epsilon but there is a compelling argument for taking its ‘hub-and-spoke’ business private in th

The second half of this decade will put the Bristol Myers Squibb management team to the test as the company prepares for losses of exclusivity (LOEs) for its three top-selling products by launching up

Venture capital fundraising by biopharmaceutical companies rose to $7.11bn in the fourth quarter of 2024, after falling to $6.46bn in Q3 from $7.95bn in Q2, according to data from Evaluate. But the ye